- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT05074719
Index Individuals in SARS-CoV-2 Prevention Research Studies (COVID-19 Index Individuals Companion Study) (IICov19PRS)
Characterization of the Index Individual for Contact Participants Enrolled in Clinical Trials of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Prevention Interventions; COVID-19 Prevention Trials Network (CoVPN) 3502-01
Clinical trials of prevention modalities for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection and coronavirus disease (COVID-19) and pneumonia are underway under separate protocol(s) for close contacts (i.e., household contacts, [e.g.,3502]) of infectious (index) individuals (3502-01).
Characterizing the index individuals within households will ascertain the risk of exposure for the contact participant. These data will be used to strengthen the precision of efficacy estimates.
This ancillary observational study will assess the cofactors for infectiousness among index individuals whose close contacts are enrolled in COVID-19 prevention clinical trials.
Additionally, this study will assess post-acute sequelae of SARS-CoV-2 infection in index individuals that are more than two weeks past their initial diagnosis.
Studieöversikt
Status
Detaljerad beskrivning
Within households, the incidence of SARS-CoV-2 is high, but the risk of transmission is characterized by exposure cofactors and transmission mitigation strategies.
Exposure cofactors are defined as cofactors that influence infectiousness of the index individual such as SARS-CoV-2 viral load, SARS-CoV-2 antibodies, and viable virus (as characterized by subgenomic RNA).
Transmission mitigation strategies are defined as modifiable cofactors that influence transmission and currently include physical distancing, social isolation, ventilation, and handwashing.
The continued progression of the pandemic has seen an increase in reports of persistent and/or delayed onset of symptoms and complications in patients well past the acute phase of COVID-19 infection. The prevalence and impacts of these post-acute sequelae of SARS-CoV-2 infection (PASC), which may continue for weeks to months after the initial COVID-19 illness, are not well understood.
Up to approximately 2,000 eligible index individuals who have close contacts (e.g., uninfected household members) in COVID-19 prevention research studies will be invited to participate. Individuals that enroll within two weeks of their diagnosis will be asked to provide a baseline mid-turbinate nasal swab for SARS-CoV-2 testing and complete questionnaires at baseline and on Days 7 and 14. Through these questionnaires, index individuals will report on the clinical course of their illness and share information about their household environment, including potential exposures there-in and any COVID-19 transmission mitigation strategies implemented (whether intentional or as part of standard home routines). Individuals that enroll more than two weeks after being diagnosed will be asked to provide a mid-turbinate nasal swab for SARS-CoV-2 testing and to complete a questionnaire reporting retrospectively on their COVID-19 illness and household environment. These individuals will also complete a questionnaire reporting on the persistence and/or delayed onset of symptoms and complications that they associate with their COVID-19 illness. Enrolled index individuals will also be invited to participate in the SARS-CoV-2 Antibody Sub-study and provide a dried blood spot specimen (at baseline) for antibody testing.
Working closely with prevention research studies, we propose to characterize the index individual level cofactors for SARS-CoV-2 transmission.
Each contact between an index individual and close contact is the unit of analysis for the research study.
The ascertainment of SARS-CoV-2 status among contacts/household members will be done through the parent prevention research study, e.g., through an existing clinical trials agreement with the CoVPN 3502/R 10933-10987-COV-2069 study.h
Across these studies, the investigators aim to assess:
- Prevalence and incidence of SARS-CoV-2 infection in the close contacts.
- Reported SARS-CoV-2 transmission mitigation strategies and exposures as assessed in the index individuals (3502-01) and household contact protocols (e.g., 3502) and the correlation between them.
- Association between the index individual SARS-CoV-2 viral load and subgenomic RNA and infection in the contact participant.
- Association of the duration of symptomatic COVID-19 in the index individual on the risk of SARS-CoV-2 transmission.
- Association of SARS-CoV-2 viral genotype in index individual to related SARS-CoV-2 genotype infection in the contact participant
- Post-acute sequelae of SARS-CoV-2 (PASC) infection in individuals that are weeks to months past their initial SARS-CoV-2 infection.
With these combined household data, effective, modifiable cofactors for household transmission can be identified to inform future post-exposure interventions. With the inclusion of data related to viral and host exposure cofactors, the investigators can increase the precision of predictive models of SARS-CoV-2 infection, adjusted for exposure and mitigation strategies. Data collected on PASC will contribute to the characterization of the long term consequences of SARS-CoV-2 infection and Post-acute COVID-19 Syndrome.
Studietyp
Inskrivning (Faktisk)
Kontakter och platser
Studieorter
-
-
Washington
-
Seattle, Washington, Förenta staterna, 98104
- University of Washington International Clinical Research Center
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Testmetod
Studera befolkning
Beskrivning
Inclusion Criteria:
- Adults 18 and older; children and adolescents 10 years of age and older, at the time of signing the informed assent with parent or guardian consent
- Willing and able to provide informed consent/assent with parental consent
- Diagnosis of SARS-CoV-2 infection using a diagnostic test with a positive result, e.g., RT-PCR, antigen test, or other test format (approved or with Emergency Use Authorization issued by the US FDA or by local health authority) and within the eligibility period of the contact's prevention research study, or is currently being assessed for COVID-19
- A close contact is being screened for enrollment or has enrolled in a SARS-CoV-2 prevention research study
- Access to a smart phone or device with internet access to complete a questionnaire or communicate with research study team
Exclusion Criteria:
- Hospitalization (current)
- No household member enrolling/enrolled in a SARS-CoV-2 prevention research study
Studieplan
Hur är studien utformad?
Designdetaljer
Kohorter och interventioner
Grupp / Kohort |
---|
Cohort A
Cohort A comprises individuals that enroll within two weeks of diagnosis of SARS-CoV-2 infection.
These individuals will be asked to provide a baseline mid-turbinate nasal swab for SARS-CoV-2 testing and complete questionnaires at baseline and on Days 7 and 14.
Through these questionnaires, index individuals will report on the clinical course of their illness and share information about their household environment, including potential exposures there-in and any COVID-19 transmission mitigation strategies implemented (whether intentional or as part of standard home routines).
Enrolled Cohort A index individuals will also be invited to participate in the SARS-CoV-2 Antibody Sub-study and provide a dried blood spot specimen (at baseline) for antibody testing.
|
Cohort B
Cohort B comprises individuals that enroll more than two weeks after diagnosis of SARS-CoV-2 infection.
These individuals will be asked to provide a mid-turbinate nasal swab for SARS-CoV-2 testing and to complete a questionnaire reporting retrospectively on their COVID-19 illness and household environment.
Through this questionnaire, index individuals will report on the clinical course of their illness and share information about their household environment, including potential exposures there-in and any COVID-19 transmission mitigation strategies implemented (whether intentional or as part of standard home routines).
These individuals will also complete a questionnaire reporting on the persistence and/or delayed onset of symptoms and complications that they associate with their COVID-19 illness.
Enrolled Cohort B index individuals will also be invited to participate in the SARS-CoV-2 Antibody Sub-study and provide a dried blood spot specimen (at baseline) for antibody testing.
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Prevalence and incidence of SARS-CoV-2 infection in the household contacts of index individuals
Tidsram: Day 1/Baseline for index individuals (3502-01); assessed weekly across 4 weeks for household contacts (3502)
|
Positive SARS-CoV-2 reverse transcription-polymerase chain reaction (RT-PCR) test, or equivalent, as assessed in the Index Individuals Companion Study (3502-01) and household contact COVID-19 Prevention Study (3502) protocols
|
Day 1/Baseline for index individuals (3502-01); assessed weekly across 4 weeks for household contacts (3502)
|
Characterization of reported SARS-CoV-2 transmission mitigation strategies
Tidsram: Across 14 days (Day 1/Baseline and Days 7 &14 Questionnaires) for index individuals, or retrospectively for individuals enrolled more than two weeks after diagnosis (3502-01); assessed at baseline and at 4 weeks for household contacts (3502)
|
Characterization and quantification of reported SARS-CoV-2 transmission mitigation strategies as assessed in the index individuals (3502-01) and household contacts (3502) protocols.
Assessment of concordance and/or correlation between index individuals' reporting and household contacts' reporting.
|
Across 14 days (Day 1/Baseline and Days 7 &14 Questionnaires) for index individuals, or retrospectively for individuals enrolled more than two weeks after diagnosis (3502-01); assessed at baseline and at 4 weeks for household contacts (3502)
|
Assessment of household exposures
Tidsram: Across 14 days (Day 1/Baseline and Days 7 &14 Questionnaires) for index individuals, or retrospectively for individuals enrolled more than two weeks after diagnosis (3502-01); assessed at baseline and at 4 weeks for household contacts (3502)
|
Characterization and quantification of household exposures assessed in the index individuals (3502-01) and household contacts (3502) protocols.
Assessment of concordance and/or correlation between index individuals' reporting and household contacts' reporting.
|
Across 14 days (Day 1/Baseline and Days 7 &14 Questionnaires) for index individuals, or retrospectively for individuals enrolled more than two weeks after diagnosis (3502-01); assessed at baseline and at 4 weeks for household contacts (3502)
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
SARS-CoV-2 viral load and/or subgenomic RNA
Tidsram: Day 1/Baseline sample (single day) for index individuals (3502-01)
|
SARS-CoV-2 semiquantitative RT-PCR and subgenomic RNA from the index individuals' mid-turbinate nasal swab (3502-01)
|
Day 1/Baseline sample (single day) for index individuals (3502-01)
|
SARS-CoV-2 genotyping within households
Tidsram: Day 1/Baseline sample (single day) for index individuals; assessed weekly for household contacts, across 4 weeks.
|
SARS-CoV-2 genotyping from a subset of index individuals' (3502-01) and household contacts' (3502) mid-turbinate nasal swab samples.
Where feasible (per genotype sample availability), genotype comparisons among index and newly infected household (i.e.
contacts) members.
|
Day 1/Baseline sample (single day) for index individuals; assessed weekly for household contacts, across 4 weeks.
|
Andra resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Serum-based antibodies to SARS-CoV-2
Tidsram: An optional, Day 1/Baseline sample (single day) for index individuals (3502-01).
|
Measurement of antibodies to SARS-CoV-2 in index individuals (3502-01) and household contacts (3502) based on dried blood spot sample(s).
|
An optional, Day 1/Baseline sample (single day) for index individuals (3502-01).
|
Samarbetspartners och utredare
Sponsor
Samarbetspartners
Utredare
- Huvudutredare: Ruanne Barnabas, MD, University of Washington
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
- Patologiska processer
- Coronaviridae-infektioner
- Nidovirales infektioner
- RNA-virusinfektioner
- Virussjukdomar
- Luftvägsinfektioner
- Luftvägssjukdomar
- Lunginflammation, Viral
- Lunginflammation
- Lungsjukdomar
- Sjukdomsegenskaper
- Sjukdom
- Svår akut respiratorisk sjukdom
- Covid-19
- Coronavirusinfektioner
- Syndrom
- Infektioner
- Smittsamma sjukdomar
Andra studie-ID-nummer
- STUDY00011462
- 3UM1AI068614-14S1 (U.S.S. NIH-anslag/kontrakt)
- 38771 (Registeridentifierare: DAIDS, NIAID, NIH)
- 3502-01 (Annat bidrag/finansieringsnummer: COVID-19 Prevention Network (CoVPN))
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Covid-19
-
Yang I. PachankisAktiv, inte rekryterandeCOVID-19 luftvägsinfektion | COVID-19 stresssyndrom | Covid-19-vaccinbiverkning | Covid-19-associerad tromboembolism | COVID-19 Post-Intensive Care Syndrome | Covid-19-associerad strokeKina
-
University of Roma La SapienzaQueen Mary University of London; Università degli studi di Roma Foro Italico och andra samarbetspartnersAvslutadPostakuta följder av covid-19 | Tillstånd efter covid-19 | Lång covid | Kroniskt covid-19 syndromItalien
-
Dr. Soetomo General HospitalIndonesia-MoH; Universitas Airlangga; Biotis Pharmaceuticals, IndonesiaRekryteringCovid-19 pandemi | Covid-19 vacciner | COVID-19 virussjukdomIndonesien
-
Indonesia UniversityRekryteringPost-COVID-19 syndrom | Lång covid | Tillstånd efter covid-19 | Post-COVID syndrom | Lång covid-19Indonesien
-
Erasmus Medical CenterDa Vinci Clinic; HGC RijswijkHar inte rekryterat ännuPost-COVID-19 syndrom | Lång covid | Lång Covid19 | Tillstånd efter covid-19 | Post-COVID syndrom | Tillstånd efter covid-19, ospecificerat | Tillstånd efter covidNederländerna
-
First Affiliated Hospital Xi'an Jiaotong UniversityShangluo Central Hospital; Ankang Central Hospital; Hanzhong Central Hospital och andra samarbetspartnersRekryteringCovid-19 | Post-COVID-19 syndrom | Postakut covid-19 | Akut covid-19Kina
-
Endourage, LLCRekryteringLång covid | Lång Covid19 | Postakut covid-19 | Long Haul COVID | Långdistans covid-19 | Postakut covid-19 syndromFörenta staterna
-
University of Witten/HerdeckeInstitut für Rehabilitationsforschung NorderneyAvslutadPost-COVID-19 syndrom | Long-COVID-19 syndromTyskland
-
University Hospital, Ioannina1st Division of Internal Medicine, University Hospital of IoanninaRekryteringCOVID-19 lunginflammation | COVID-19 luftvägsinfektion | Covid-19 pandemi | COVID-19 akut andnödsyndrom | Covid-19-associerad lunginflammation | COVID 19 associerad koagulopati | COVID-19 (Coronavirus sjukdom 2019) | Covid-19-associerad tromboembolismGrekland